Moderna Stock Fundamentals
| 0QF Stock | EUR 40.00 1.71 4.10% |
Moderna fundamentals help investors to digest information that contributes to Moderna's financial success or failures. It also enables traders to predict the movement of Moderna Stock. The fundamental analysis module provides a way to measure Moderna's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Moderna stock.
Moderna |
Moderna Company Current Valuation Analysis
Moderna's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Moderna Current Valuation | 69.44 B |
Most of Moderna's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Moderna is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Moderna has a Current Valuation of 69.44 B. This is 383.44% higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The current valuation for all Germany stocks is significantly lower than that of the firm.
Moderna Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Moderna's current stock value. Our valuation model uses many indicators to compare Moderna value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Moderna competition to find correlations between indicators driving Moderna's intrinsic value. More Info.Moderna is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.46 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Moderna is roughly 2.16 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Moderna's earnings, one of the primary drivers of an investment's value.Moderna Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Moderna's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Moderna could also be used in its relative valuation, which is a method of valuing Moderna by comparing valuation metrics of similar companies.Moderna is currently under evaluation in current valuation category among its peers.
Moderna Fundamentals
| Return On Equity | 0.5 | |||
| Return On Asset | 0.23 | |||
| Profit Margin | 0.43 % | |||
| Operating Margin | 0.49 % | |||
| Current Valuation | 69.44 B | |||
| Shares Outstanding | 385 M | |||
| Shares Owned By Insiders | 9.49 % | |||
| Shares Owned By Institutions | 68.06 % | |||
| Price To Earning | 237.44 X | |||
| Price To Book | 4.46 X | |||
| Price To Sales | 3.48 X | |||
| Revenue | 19.26 B | |||
| Gross Profit | 10.55 B | |||
| EBITDA | 9.77 B | |||
| Net Income | 8.36 B | |||
| Cash And Equivalents | 7.99 B | |||
| Cash Per Share | 19.80 X | |||
| Total Debt | 603 M | |||
| Debt To Equity | 0.09 % | |||
| Current Ratio | 1.24 X | |||
| Book Value Per Share | 49.67 X | |||
| Cash Flow From Operations | 4.98 B | |||
| Earnings Per Share | 22.69 X | |||
| Number Of Employees | 3.9 K | |||
| Beta | 1.64 | |||
| Market Capitalization | 50.28 B | |||
| Total Asset | 25.86 B | |||
| Z Score | 49.8 | |||
| Net Asset | 25.86 B |
About Moderna Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Moderna's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moderna using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moderna based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. MODERNA INC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1800 people.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Moderna Stock
When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Moderna Stock please use our How to Invest in Moderna guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.